샘플 요청 목록

 카트 문의
시장보고서
상품코드
1791599

세계의 CRISPR 기반 유전자 편집 시장

CRISPR-based Gene Editing
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 172 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 CRISPR 기반 유전자 편집 시장은 2030년까지 110억 달러에 이를 전망

2024년에 44억 달러로 추정된 CRISPR 기반 유전자 편집 세계 시장은 2030년에는 110억 달러에 이르고, 분석 기간인 2024-2030년 CAGR은 16.3%를 보일 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 CRISPR 키트 및 시약은 CAGR18.3%를 나타내고, 분석 기간 종료까지 77억 달러에 이를 것으로 예측됩니다. CRISPR 라이브러리 분야의 성장률은 분석 기간 CAGR 12.3%로 추정됩니다.

미국 시장은 12억 달러로 추정, 중국은 CAGR 15.3%를 보일 것으로 예측

미국의 CRISPR 기반 유전자 편집 시장은 2024년에 12억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 17억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 15.3%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 15.3%와 13.9%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 11.7%를 보일 전망입니다.

세계의 CRISPR 유전자 편집 시장 - 주요 동향 및 촉진요인 정리

CRISPR 유전자 편집이 생명공학을 변화시키는 이유는 무엇일까? 정밀의료의 획기적인 발전을 탐구하다

세계 CRISPR을 통한 유전자 편집 시장은 유전공학의 발전, 생명공학 연구에 대한 자금 지원 증가, 정밀의료에 대한 수요 증가로 인해 빠르게 성장하고 있습니다. CRISPR(Clustered Regularly Interspaced Short Palindromic Repeats) 기술은 유전자 편집 분야에 혁명을 일으켜 높은 정확도와 효율적인 유전자 변형을 가능하게 했습니다. 겸상 적혈구 빈혈, 근이영양증, 낭포성 섬유증과 같은 유전성 질환을 치료하기 위한 유전자 치료 용도의 급격한 증가는 시장 성장의 주요 촉진요인으로 작용하고 있습니다. 또한, CRISPR은 암 면역치료에서 중요한 역할을 하고 있으며, 종양을 보다 효과적으로 표적으로 삼을 수 있도록 면역세포를 변형시킬 수 있습니다. 합성생물학에 대한 관심이 높아지면서 CRISPR은 유전자 변형 작물, 바이오연료 생산을 위한 미생물 공학, 내병성 가축 개발에도 활용되고 있습니다.

시장을 선도하는 CRISPR 기반 용도는? 주요 부문별 분석

시장 세분화는 치료용, 농업용, 산업용으로 구분됩니다. 유전질환의 원인인 유전자 변이를 교정하기 위해 CRISPR의 활용이 증가함에 따라 유전자 치료와 재생의학을 포함한 치료 분야가 시장을 주도하고 있습니다. CRISPR은 작물 수확량 향상, 내병성 식물 개발, 식량 안보 개선에 사용되고 있습니다. 산업 생명공학 분야도 CRISPR의 혜택을 받고 있으며, 효소 생산, 바이오연료 합성, 합성 생물학 혁신에 적용되고 있습니다. 셜록(SHERLOCK)이나 디텍터(DETECTR)와 같은 CRISPR 기반 진단약의 출현은 신속하고 비용 효율적인 질병 검출을 가능하게 하여 시장의 범위를 더욱 확장하고 있습니다.

AI, 나노기술, 바이오인포매틱스의 역할, CRISPR을 통한 유전자 편집을 주도하는 혁신은 어떻게 이루어지고 있는가?

CRISPR 산업은 인공지능(AI), 나노기술, 바이오인포매틱스(Bioinformatics)의 통합으로 진화하고 있습니다. AI 유전자 편집 알고리즘은 정확도를 높이고, 오프 타겟 효과의 위험을 줄이며, 편집 효율을 향상시킵니다. Cas12, Cas13 등 차세대 Cas 효소의 개발로 CRISPR의 능력은 DNA 편집에 그치지 않고 RNA 변형까지 확대되었습니다. 지질 나노입자 및 바이러스 벡터를 포함한 나노기술 기반의 CRISPR 전달 시스템은 유전자 편집 치료의 효율성과 안전성을 향상시키고 있습니다. 또한, 생물정보학 도구의 발전으로 연구자들은 CRISPR 상호 작용을 보다 정확하게 모델링하고 유전자 편집 워크플로우를 최적화할 수 있게 되었습니다. DNA 염기서열을 바꾸지 않고 유전자 발현을 교정하는 CRISPR 기반 후성유전학적 편집의 등장은 복잡한 질병 치료에 새로운 가능성을 제시하고 있습니다.

CRISPR 유전자 편집 시장의 성장을 이끄는 요인은 무엇인가? 주요 시장 영향요인에 대한 설명

CRISPR을 통한 유전자 편집 시장의 성장은 생명공학 연구에 대한 투자 증가, 질병 치료에 대한 응용 확대, 전달 메커니즘의 발전에 의해 촉진되고 있습니다. 제약회사와 생명공학 기업들의 유전자 치료 프로그램 확대는 시장의 상업적 잠재력을 강화하고 있습니다. 유전자 편집 연구에 대한 정부의 자금 지원과 규제 지원도 기술 혁신을 가속화하고 있습니다. CRISPR을 활용해 환자 맞춤형 치료법을 개발하는 맞춤의료에 대한 수요가 증가하면서 시장 성장에 더욱 박차를 가하고 있습니다. 그러나 인간 생식세포 계통 편집에 대한 윤리적 우려와 규제적 조사는 여전히 중요한 과제입니다. 지속적인 과학의 발전과 유전자 편집 용도의 광범위한 수용으로 CRISPR 시장은 향후 몇 년 동안 혁신적인 성장을 보일 것으로 예측됩니다.

부문

제품(CRISPR 키트 및 시약, CRISPR 라이브러리), 용도(생물의학 용도, 농업 용도), 최종 용도(제약 기업 및 바이오테크놀러지 기업 최종 용도, 학술기관 및 연구기관 최종 용도, 계약 연구기관 최종 용도)

조사 대상 기업 예

  • Beam Therapeutics
  • Caribou Biosciences
  • Cellectis
  • Colossal Biosciences
  • CRISPR Therapeutics
  • Editas Medicine
  • eGenesis
  • Graphite Bio
  • Inari Agriculture
  • Inscripta
  • Intellia Therapeutics
  • Mammoth Biosciences
  • Pairwise
  • Poseida Therapeutics
  • Precision BioSciences
  • Sangamo Therapeutics
  • SNIPR Biome
  • Synthego Corporation
  • Tropic Biosciences
  • Verve Therapeutics

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장과 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

LSH 25.08.21

Global CRISPR-based Gene Editing Market to Reach US$11.0 Billion by 2030

The global market for CRISPR-based Gene Editing estimated at US$4.4 Billion in the year 2024, is expected to reach US$11.0 Billion by 2030, growing at a CAGR of 16.3% over the analysis period 2024-2030. CRISPR Kits & Reagents, one of the segments analyzed in the report, is expected to record a 18.3% CAGR and reach US$7.7 Billion by the end of the analysis period. Growth in the CRISPR Libraries segment is estimated at 12.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 15.3% CAGR

The CRISPR-based Gene Editing market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 15.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.3% and 13.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.7% CAGR.

Global CRISPR-Based Gene Editing Market - Key Trends & Drivers Summarized

Why Is CRISPR-Based Gene Editing Transforming Biotechnology? Exploring the Breakthroughs in Precision Medicine

The global CRISPR-based gene editing market has witnessed rapid expansion, driven by advancements in genetic engineering, increased funding for biotechnology research, and the growing demand for precision medicine. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionized the field of gene editing, enabling highly precise and efficient genetic modifications. The surge in gene therapy applications, aimed at treating genetic disorders such as sickle cell anemia, muscular dystrophy, and cystic fibrosis, has been a key driver of market growth. Additionally, CRISPR is playing an instrumental role in cancer immunotherapy, enabling the modification of immune cells to target tumors more effectively. With increasing interest in synthetic biology, CRISPR is also being utilized in the development of genetically engineered crops, microbial engineering for biofuel production, and disease-resistant livestock.

Which CRISPR-Based Applications Are Leading the Market? A Breakdown of Key Segments

The CRISPR-based gene editing market is segmented into therapeutic, agricultural, and industrial applications. The therapeutic segment, which includes gene therapy and regenerative medicine, dominates the market, as CRISPR is increasingly used to correct genetic mutations responsible for inherited diseases. Agricultural applications are also witnessing significant growth, with CRISPR being used to enhance crop yield, develop disease-resistant plants, and improve food security. The industrial biotechnology sector has also benefited from CRISPR, with applications in enzyme production, biofuel synthesis, and synthetic biology innovations. The emergence of CRISPR-based diagnostics, such as SHERLOCK and DETECTR, has further expanded the market’s scope by enabling rapid and cost-effective disease detection.

How Is Innovation Driving CRISPR-Based Gene Editing? The Role of AI, Nanotechnology & Bioinformatics

The CRISPR industry is evolving with the integration of artificial intelligence (AI), nanotechnology, and bioinformatics. AI-driven gene editing algorithms have enhanced precision, reducing the risk of off-target effects and improving editing efficiency. The development of next-generation Cas enzymes, such as Cas12 and Cas13, has expanded CRISPR’s capabilities beyond DNA editing to include RNA modifications. Nanotechnology-based CRISPR delivery systems, including lipid nanoparticles and viral vectors, are improving the efficiency and safety of gene-editing therapies. Additionally, advancements in bioinformatics tools are enabling researchers to model CRISPR interactions more accurately, optimizing gene-editing workflows. The rise of CRISPR-based epigenetic editing, which modifies gene expression without altering DNA sequences, has opened new possibilities for treating complex diseases.

What’s Driving the Growth of the CRISPR-Based Gene Editing Market? Key Market Influencers Explained

The growth in the CRISPR-based gene editing market is fueled by rising investment in biotechnology research, increasing applications in disease treatment, and advancements in delivery mechanisms. The expansion of gene therapy programs by pharmaceutical and biotech companies has strengthened the market’s commercial potential. Government funding initiatives and regulatory support for genome editing research have also accelerated innovation. The growing demand for personalized medicine, which leverages CRISPR to develop patient-specific treatments, has further boosted market growth. However, ethical concerns and regulatory scrutiny regarding human germline editing remain key challenges. With ongoing scientific advancements and broader acceptance of gene-editing applications, the CRISPR market is expected to witness transformative growth in the coming years.

SCOPE OF STUDY:

The report analyzes the CRISPR-based Gene Editing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Products (CRISPR Kits & Reagents, CRISPR Libraries); Application (Biomedical Applications, Agricultural Applications); End-Use (Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use, Contract Research Organizations End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

  • Beam Therapeutics
  • Caribou Biosciences
  • Cellectis
  • Colossal Biosciences
  • CRISPR Therapeutics
  • Editas Medicine
  • eGenesis
  • Graphite Bio
  • Inari Agriculture
  • Inscripta
  • Intellia Therapeutics
  • Mammoth Biosciences
  • Pairwise
  • Poseida Therapeutics
  • Precision BioSciences
  • Sangamo Therapeutics
  • SNIPR Biome
  • Synthego Corporation
  • Tropic Biosciences
  • Verve Therapeutics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • CRISPR-based Gene Editing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Investment in Gene Therapy and Precision Medicine Spurs Market Growth for CRISPR-based Gene Editing
    • Surge in Biotechnology and Pharmaceutical Research Propels Demand for CRISPR as a Leading Gene Editing Tool
    • The Growing Need for Targeted and Personalized Treatments Expands Addressable Market for CRISPR Gene Editing Applications
    • Regulatory Advancements and Easing of Gene Editing Guidelines Accelerates the Commercialization of CRISPR-Based Therapies
    • The Expansion of Gene Therapy Clinical Trials Strengthens Business Case for CRISPR in Therapeutic Development
    • Rising Prevalence of Genetic Disorders and Chronic Diseases Drives Accelerated Adoption of CRISPR in Healthcare Solutions
    • Increasing Focus on Agricultural Biotechnology Strengthens the Case for CRISPR in Crop Improvement and Livestock Enhancement
    • Technological Advancements in CRISPR Delivery Mechanisms Propel Market Adoption in Both Clinical and Agricultural Sectors
    • The Shift Toward Sustainable Agriculture Drives Market Growth for CRISPR in Genetically Modified Crops with Enhanced Yield and Disease Resistance
    • Increased Investment in CRISPR Startups and Biotech Companies Spurs Innovation in Gene Editing Techniques
    • The Rise of CRISPR-Cas9-based Diagnostics and Point-of-Care Solutions Generates Demand for Gene Editing Technologies in Medical Devices
    • Public and Private Sector Collaborations and Funding Drive Growth in CRISPR-based Research and Development Projects
    • Regulatory and Ethical Challenges Surrounding Germline Editing Create Barriers to Market Growth in Certain Regions
    • Rising Demand for CRISPR in Cell and Gene Therapy Applications Expands Opportunities for Market Adoption in Regenerative Medicine
    • The Increasing Role of CRISPR in Infectious Disease Research and Treatment Drives New Opportunities in Global Health
    • Integration of CRISPR with AI and Machine Learning Strengthens the Business Case for Highly Targeted Gene Editing Solutions
    • Ethical Considerations and Public Perception of Gene Editing Technologies Throw the Spotlight on the Need for Responsible Innovation
    • Rising Demand for Non-invasive Gene Editing Solutions Spurs Growth in CRISPR-based Applications with Reduced Risk of Side Effects
    • The Need for Faster, More Accurate Genetic Research Drives Adoption of CRISPR in Academic and Commercial Research Laboratories
    • Advances in Genome Sequencing and Genomic Data Infrastructure Sustain Growth in the CRISPR-based Gene Editing Ecosystem
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World CRISPR-based Gene Editing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for CRISPR-based Gene Editing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for CRISPR Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for CRISPR Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for CRISPR Libraries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for CRISPR Libraries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biomedical Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Biomedical Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Agricultural Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Agricultural Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Contract Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • CRISPR-based Gene Editing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 18: USA Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 19: USA 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
  • CANADA
    • TABLE 24: Canada Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Canada 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
  • JAPAN
    • CRISPR-based Gene Editing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 30: Japan Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Japan 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
    • TABLE 34: Japan Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
  • CHINA
    • CRISPR-based Gene Editing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 36: China Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: China 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
    • TABLE 40: China Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
  • EUROPE
    • CRISPR-based Gene Editing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 42: Europe Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 43: Europe 6-Year Perspective for CRISPR-based Gene Editing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
  • FRANCE
    • CRISPR-based Gene Editing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
    • TABLE 52: France Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: France 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
    • TABLE 54: France Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
  • GERMANY
    • CRISPR-based Gene Editing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
    • TABLE 58: Germany Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Germany 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
    • TABLE 60: Germany Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
    • TABLE 64: Italy Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Italy 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
    • TABLE 66: Italy Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
  • UNITED KINGDOM
    • CRISPR-based Gene Editing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
    • TABLE 70: UK Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: UK 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
    • TABLE 72: UK Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Europe 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
  • ASIA-PACIFIC
    • CRISPR-based Gene Editing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Asia-Pacific 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
    • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Asia-Pacific 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 86: Rest of World Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of World 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
    • TABLE 88: Rest of World Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of World 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제